Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | GLRA1 | P23415 | 2/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898263 | 0.72 | PLA2G2A (0.51) | THRATHRBGLRA1RXRA | |
| SCHEMBL4888400 | 0.70 | GLRA1 (0.54) | THRATHRBGLRA1PARP10FFAR1 | |
| SCHEMBL24499213 | 0.70 | PARP10 (0.36) | THRATHRBPARP10PARP15 | |
| SCHEMBL711186 | 0.68 | GCK (0.67) | PARP10PARP15FFAR1GCKXDH | |
| SCHEMBL8194213 | 0.68 | THRA (0.62) | THRATHRBPARP10PARP15FFAR1 | |
| SCHEMBL6720844 | 0.68 | THRA (0.51) | THRATHRBPARP10PARP15RHEB | |
| SCHEMBL30261449 | 0.67 | SCN9A (0.49) | PARP10PARP15 | |
| SCHEMBL4890148 | 0.67 | ALDH1A1 (0.43) | THRATHRBGLRA1RXRA | |
| SCHEMBL4898911 | 0.66 | GLRA1 (0.58) | THRATHRBGLRA1PARP10PARP15 | |
| SCHEMBL4899367 | 0.66 | THRB (0.71) | THRATHRBPARP10PARP15FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | THRA 559/4885THRB 792/4885GLRA1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.